Last reviewed · How we verify
TLC599
TLC599 is a liposomal formulation of a chemotherapeutic agent.
TLC599 is a liposomal formulation of a chemotherapeutic agent. Used for Treatment of various types of cancer.
At a glance
| Generic name | TLC599 |
|---|---|
| Also known as | TLC599 Injection |
| Sponsor | Taiwan Liposome Company |
| Drug class | chemotherapeutic agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of TLC599 is not publicly available, but it is believed to work by inhibiting cancer cell growth and inducing apoptosis. The liposomal formulation is designed to improve the delivery and efficacy of the chemotherapeutic agent.
Approved indications
- Treatment of various types of cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee (PHASE2)
- Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain (PHASE3)
- Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients (PHASE2)
- Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TLC599 CI brief — competitive landscape report
- TLC599 updates RSS · CI watch RSS
- Taiwan Liposome Company portfolio CI